Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. Everson RG, et al. Among authors: ellingson bm. Nat Commun. 2024 May 8;15(1):3882. doi: 10.1038/s41467-024-48073-y. Nat Commun. 2024. PMID: 38719809 Free PMC article. Clinical Trial.
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.
Sim HW, Wachsmuth L, Barnes EH, Yip S, Koh ES, Hall M, Jennens R, Ashley DM, Verhaak RG, Heimberger AB, Rosenthal MA, Hovey EJ, Ellingson BM, Tognela A, Gan HK, Wheeler H, Back M, McDonald KL, Long A, Cuff K, Begbie S, Gedye C, Mislang A, Le H, Johnson MO, Kong BY, Simes JR, Lwin Z, Khasraw M. Sim HW, et al. Among authors: ellingson bm. Neurooncol Adv. 2023 Sep 22;5(1):vdad124. doi: 10.1093/noajnl/vdad124. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37841696 Free PMC article.
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group.
Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M. Albert NL, et al. Among authors: ellingson bm. Lancet Oncol. 2024 Jan;25(1):e29-e41. doi: 10.1016/S1470-2045(23)00525-9. Lancet Oncol. 2024. PMID: 38181810 Review.
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
Sarkaria JN, Ballman KV, Kizilbash SH, Sulman EP, Giannini C, Friday BB, Butowski NA, Mohile NA, Piccioni DE, Battiste JD, Drappatz J, Campian JL, Mashru S, Jaeckle KA, O'Brien BJ, Dixon JG, Kabat BF, Laack NL, Hu LS, Kaufmann T, Kumthekar P, Ellingson BM, Anderson SK, Galanis E. Sarkaria JN, et al. Among authors: ellingson bm. JAMA Oncol. 2024 Oct 31:e244361. doi: 10.1001/jamaoncol.2024.4361. Online ahead of print. JAMA Oncol. 2024. PMID: 39480453
Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma.
Oshima S, Yao J, Bobholz S, Nagaraj R, Raymond C, Teraishi A, Guenther AM, Kim A, Sanvito F, Cho NS, C Eldred BS, Connelly JM, Nghiemphu PL, Lai A, Salamon N, Cloughesy TF, LaViolette PS, Ellingson BM. Oshima S, et al. Among authors: ellingson bm. CNS Oncol. 2024 Dec 31;13(1):2415285. doi: 10.1080/20450907.2024.2415285. Epub 2024 Nov 13. CNS Oncol. 2024. PMID: 39535237 Free PMC article.
286 results